Scientific Program
Click here to download the meeting program
Sunday, May 15th |
||
| 4:00-8:00 | Registration | |
6:30-7:30
7:30-8:30 |
Keynote Address: Fokko van der Woude Welcome Reception |
Cees Kallenberg, MD, PhD |
Monday, May 16th |
||
| 7:30-8:00 | Continental Breakfast | |
| 8:00-8:15 | Introduction and Welcome | |
| 8:15-9:30 | SESSION 1: Nomenclature and Classification of Vasculitis Moderators: Wolfgang Gross, MD & Eric Matteson, MD |
|
| 8:15-8:35 | Overview of Nomenclature and Classification of Vasculitis | J. Charles Jennette, MD |
| 8:35-8:55 | Update on ACR/EULAR Classifications & Diagnostic Criteria | Raashid Luqmani, MD |
| 8:55-9:15 | Pathologic Classification of ANCA GN | Ingeborg Bajema, MD, PhD |
| 9:15-9:30 | Open Discussion | |
| 9:30-10:30 | SESSION 2: Origins of Autoimmunity Moderators: Cees Kallenberg, MD, PhD & Charles Pusey, DSc, FRCP |
|
| 9:30-10:10 | Autoantigen Conformopathy | Billy Hudson, PhD |
| 10:10-10:30 | Epigenetics and Complementary Proteins | Ronald J. Falk, MD |
| 10:30-11:00 | SESSION 3: Status of European GWAS Kenneth Smith, PhD | |
| 11:00-12:00 | POSTER SESSION 1
|
|
| 12:00-1:45 | Lunch Break | |
| 1:45-3:00 | SESSION 4A: Serology in the Classification and Management of Vasculitis Moderators: Franco Ferrario, MD & Judy A. Savige, MD, PhD |
|
| 1:45-2:05 | Optimum Approaches to Clinical ANCA Testing | Elena Csernok, PhD |
| 2:05-3:00 | Abstract Presentations
|
|
| 1:45-3:00 | SESSION 4B: Membrane Antigen Biology Moderators: Jorgen Wieslander, MD, PhD & Jan-Willem Cohen-Tervaert, MD, PhD |
|
| 1:45-2:00 | The Role of Membrane Antigens in ANCA Disease: The Berlin Perspective | Ralph Kettritz, MD |
| 2:00-2:15 | The Role of Membrane Antigens in ANCA Disease: The Lund Perspective | Thomas Hellmark, PhD |
| 2:15-2:30 | The Role of Autoantigen Protein Partners in ANCA Disease | Véronique Witko-Sarsat, PhD |
| 2:30-3:00 | Open Discussion | |
| 3:00-4:00 | POSTER SESSION 2
|
|
| 4:00-4:30 | Refreshment Break | |
| 4:30-6:00 | SESSION 5A Global Epidemiology of Vasculitis Moderators: Susan L. Hogan, PhD, MPH & Sofia Lionaki, MD |
|
| 4:30-4:50 | ANCA Disease in Asia | Ming-Hui Zhao, MD, PhD |
| 4:50-6:00 | Abstract Presentations
|
|
| 4:30-6:00 | SESSION 5B: B-Cells and T-Cells in Autoimmunity Moderators: Donna Bunch, PhD & Peter Hewins, MD, PhD |
|
| 4:30-4:45 | T Cells in the Induction of Human Autoimmune Vasculitis | Peter Lamprecht, MD |
| 4:45-5:00 | B-Cells in the Induction of Human Autoimmune Vasculitis | Alan Salama, MD |
| 5:00-6:00 | Abstract Presentations
|
|
Tuesday, May 17th |
||
| 7:30-8:00 | Continental Breakfast | |
| 8:00-9:30 | SESSION 6: Pathogenesis of Vasculitis Moderators: Jan-Willem Cohen-Tervaert, MD, PhD & Kazuo Suzuki, PhD |
|
| 8:00-8:20 | Pathogenesis of Giant Cell Arteritis | Cornelia Weyand, MD, PhD |
| 8:20-8:40 | Pathogenesis of Kawasaki Disease | Kei Takahashi, MD |
| 8:40-9:00 | Pathogenesis of ANCA | Caroline Savage, MD, PhD |
| 9:00-9:20 | Translation of Pathogenic Understanding to Novel Therapies | Patrick N. Nachman, MD |
| 9:20-9:30 | Abstract Presentation
|
|
| 9:30-11:00 | SESSION 7: Induction Therapy in ANCA Vasculitis Moderators: Patrick N. Nachman, MD & Luis Felipe Flores-Suarez, MD, PhD |
|
| 9:30-9:50 | Rituximab in Induction Therapy for ANCA Vasculitis | John Niles, MD |
| 9:50-10:10 | Cyclophosphamide in Induction Therapy for ANCA Vasculitis | Carol Langford, MD |
| 10:10-11:00 | Abstract Presentations
|
|
| 11:00-12:00 | Poster Session 3
|
|
| 12:00-1:45 | Lunch Break | |
| 1:45-3:00 | SESSION 8A: Predictive, Diagnostic and Prognostic Biomarkers of Vasculitis - Part 1 Moderators: Alfred Mahr, MD and Mary Anne Dooley, MD, MPH |
|
| 1:45-2:05 | Diagnostic Markers of Nervous System Vasculitis | Leonard H. Calabrese, DO |
| 2:05-2:25 | Diagnostic Markers of Giant Cell Arteritis | Loic Guillevin, MD |
| 2:25-3:00 | Abstract Presentations
|
|
| 1:45-3:00 | SESSION 8B: Genetics Moderators: Jiajin Yang, MD & Lorraine Harper, MD |
|
| 1:45-3:00 | Abstract Presentations
|
|
| 3:00-4:00 | Poster Session 4
|
|
| 4:00-4:30 | Refreshment Break | |
| 4:30-6:00 | SESSION 9A : Predictive, Diagnostic and Prognostic Biomarkers of Vasculitis - Part 2 Moderators: David Henke and Brent Senior, MD |
|
| 4:30-4:45 | Diagnostic Markers of Upper Respiratory Tract Vasculitis | Niels Rasmussen, MD |
| 4:45-5:00 | Diagnostic Markers of Lung Vasculitis | Ulrich Specks, MD |
| 5:00-5:15 | Diagnostic Markers of Churg-strauss: ANCA Positive Versus ANCA Negative Christian Pagnoux, MD, PhD | Christian Pagnoux, MD, PhD |
| 5:15-6:00 | Abstract Presentations
|
|
| 4:30-6:00 | SESSION 9B: Animal Models Moderators: Hong Xiao, MD & Mark Little, MD, PhD |
|
| 4:30-4:50 | Animal Models of ANCA-AAV: An Overview | Peter Herringa, PhD |
| 4:50-5:10 | The Collaborative Cross: A Community Resource for Biomedical Research | Fernando Pardo Manuel de Villena |
| 5:10-6:00 | Abstract Presentations
|
|
Wednesday, May 18th |
||
| 7:30-8:00 | Continental Breakfast | |
| 8:00-9:00 | SESSION 10: The Lamp2 Controversy Moderators: Lorraine Harper, MD & Thomas Hellmark, PhD |
|
| 8:00-8:20 | Autoantibodies to hLAMP-2 | Renate Kain, MD |
| 8:20-8:40 | Is LAMP-2 a Target of ANCA? | Gloria Preston, PhD |
| 8:40-9:00 | Open Discussion | |
| 9:00-10:30 | SESSION 11: Clinical Studies: Present and Future Moderators: Maria Cid, MD & Melanie S. Joy, PharmD, PhD |
|
| 9:00-9:15 | Update on the Activities of the Vasculitis Clinical Research Consortium | Peter Merkel, MD, MPH |
| 9:15-9:30 | Rituximab Trials | David Jayne, MD |
| 9:30-9:45 | Clinical Trials Update: Studies from the European Vasculitis Study Group | Kirsten de Groot, MD, PhD |
| 9:45-10:30 | Abstract Presentations
|
|
| 10:30-11:30 | SESSION 12: Endothelium and Microparticles Moderators: Vladimir Tesar, MD, PhD & Alan Salama, MD |
|
| 10:30-10:50 | Neutrophil/ Endothelium Cross-Activation in Presence of ANCA | Philip LeSavre, MD |
| 10:50-11:10 | Microparticles in ANCA Vasculitis | Marion Haubitz, MD |
| 11:10-11:30 | Abstract Presentations
|
|
| 11:30-1:00 | Lunch Break | |
| 1:00-2:00 | SESSION 13: Neutrophil Activation in Vasculitis Moderator: Kerstin Westman, MD, PhD |
|
| 1:00-1:20 | Natural ANCA Antibodies | Marten Segelmark, MD |
| 1:20-2:00 | Abstract Presentations
|
|
| 2:00-3:00 | SESSION 14: Clinical Vasculitis Phenotypes, Risk Factors and Outcomes Moderators: Gina Gregorini, MD & Joanne M. Jordan, MD, MPH |
|
| 2:00-3:00 | Abstract Presentations
|
|
| 3:00-4:00 | SESSION 15: Looking Ahead and Passing The Baton | |
| 3:00-3:30 | What Does the Future Hold for Clinical Studies in Vasculitis? | Gary Hoffman, MD, MS |
| 3:30-4:00 | What Does the Future Hold for Basic Science Studies in Vasculitis? | Ronald J. Falk, MD |
